Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Gait disturbance, Muscular weakness, Myalgia
Clinical narrative: hard to walk/had to brace herself with her hands on the wall.; dizziness; muscle pain/muscle ache; muscle weakness; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (muscle weakness), GAIT DISTURBANCE (hard to walk/had to brace herself with her hands on the wall.), DIZZINESS (dizziness) and MYALGIA (muscle pain/muscle ache) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 059H21A, 038B21A, 011821A and 030620A) for COVID-19 vaccination.     The patient had no allergies and never ever had COVID + test or diagnosis. It was unknown if any other vaccines were given within 1 month prior to Moderna COVID-19 vaccine to the patient.  The patient's past medical history included Knee replacement (due to osteoarthritis) on 20-Aug-2021, Hand operation (at the base of the left thumb) on 11-Jan-2022 and Tendon repair (they removed the trapezium bone and did tendon repair) on 11-Jan-2022. Concurrent medical conditions included Osteoarthritis (10 to 12 years ago or longer, condition Worsening), Coronary artery disease (No change in status reported .), Depression (No change in status reported .), Eye disorder (Age related eye disease, No change in status reported .) and Immunosuppression (Immunologically suppressed, No change in status reported .). Concomitant products included ROSUVASTATIN CALCIUM (CRESTOR), EZETIMIBE (ZETIA), DULOXETINE HYDROCHLORIDE (CYMBALTA), ASCORBIC ACID, TOCOPHERYL ACETATE, XANTOFYL, ZEAXANTHIN, ZINC (AREDS), VITAMIN D [VITAMIN D NOS] and ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 27-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 07-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 07-Apr-2022, the patient experienced MUSCULAR WEAKNESS (muscle weakness) and MYALGIA (muscle pain/muscle ache). On 08-Apr-2022, the patient experienced GAIT DISTURBANCE (hard to walk/had to brace herself with her hands on the wall.) and DIZZINESS (dizziness). At the time of the report, MUSCULAR WEAKNESS (muscle weakness) and MYALGIA (muscle pain/muscle ache) had not resolved and GAIT DISTURBANCE (hard to walk/had to brace herself with her hands on the wall.) and DIZZINESS (dizziness) outcome was unknown.            Other concomitant medications reported included Areds eye vitamins, two fish oils and Vitamin B + Folic for unknown indications.  The patient stated 10 hours after receiving the second Moderna booster dose 07-Apr-2022, the patient experienced the same thing happened to their whole body including muscle aches, muscle pain, and muscle weakness. On 08-Apr-2022, the patient experienced more muscle weakness and muscle aches, and mentioned it was hard to walk. The patient also reported dizziness and stated the patient had to brace themselves with their hands on the wall. The patient said the reactions were getting worse and worse after each dose.  It was also reported that the patient had experienced a similar event in the past with other Moderna injections.  Reportedly, the patient saw their physician on 05-May-2022.   The patient's height was reported as 5 feet 5 inch.  No treatment information was provided.   This case was linked to MOD-2022-560454, MOD-2022-560457, MOD-2022-560462 (Patient Link).